According to filings with the U.S. Securities and Exchange Commission, Pulmotect is raising $3,511,000.00 in new funding. Sources indicate as part of senior management President and Chief Operating Officer, Brenton Scott played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pulmotect
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the bodys innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens. Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lungs to provide immediate and effective protection in animal models against all major classes of pathogens. Phase I/2a clinical trials demonstrated that PUL-042 was well tolerated in healthy individuals and subjects with COPD. Two phase 2 studies have completed enrollment for the prevention and treatment of COVID-19 with funding from the Department of Defense, with data read outs in Q3/Q4 2021. Phase 2 studies are being planned to assess the effectiveness of PUL-042 in preventing respiratory complications and improving outcomes in immunocompromised cancer patients.

To learn more about Pulmotect, visit http://pulmotect.com/

Contact:
Brenton Scott, President and Chief Operating Officer
713-579-9226
https://www.linkedin.com/in/brenton-scott-762654b1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.